Enanta Pharmaceuticals, Inc. (ENTA) Q4 2026 earnings results
Enanta Pharmaceuticals, Inc. (ENTA) reported Q4 2026 results on Nov 16, 2026, 4:10:15 PM ET: GAAP EPS -$0.81 vs. -$0.77 expected (miss by 5.2%); revenue $12.87M vs. $15.72M expected (miss by 18.1%), according to Nexqual's capture of the SEC 8-K filing (nexqual.com/earnings/2026-11-16/ENTA). Outlook: The company expects its current cash, cash equivalents and marketable securities, as well as its retained portion of future royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs into fiscal 2029.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | -$0.81 | -$0.77 | Miss by 5.2% |
| Revenue | $12.87M | $15.72M | Miss by 18.1% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 16, 2026, 4:10:15 PM ET. Nexqual published them 17 min 49 s after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue fell 14.9% from $15.13M.
Stock reaction
The results came out after the market closed. ENTA closed at $8.69 on November 17, 2026, down 18.6% from its $10.67 close on November 16, 2026 before the results. Latest: $8.24 as of 3:31 PM ET, −22.8% since the pre-release close.
Questions and answers
Did Enanta Pharmaceuticals, Inc. beat earnings expectations?
No. Enanta Pharmaceuticals, Inc. reported GAAP EPS of -$0.81 against an average analyst estimate of -$0.77 (miss by 5.2%), and revenue of $12.87M against $15.72M expected (miss by 18.1%). Source: Nexqual (nexqual.com/earnings/2026-11-16/ENTA).
What were Enanta Pharmaceuticals, Inc.'s Q4 2026 earnings and revenue?
GAAP diluted EPS of -$0.81 and revenue of $12.87M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue fell 14.9% from $15.13M. Source: Nexqual (nexqual.com/earnings/2026-11-16/ENTA).
When did Enanta Pharmaceuticals, Inc. report Q4 2026 earnings?
Nov 16, 2026, 4:10:15 PM ET, in an SEC 8-K filing (Item 2.02). Source: Nexqual (nexqual.com/earnings/2026-11-16/ENTA).
How did ENTA stock react to the earnings?
The results came out after the market closed. ENTA closed at $8.69 on November 17, 2026, down 18.6% from its $10.67 close on November 16, 2026 before the results. Latest: $8.24 as of 3:31 PM ET, −22.8% since the pre-release close. Source: Nexqual (nexqual.com/earnings/2026-11-16/ENTA).
What did Enanta Pharmaceuticals, Inc. say about its outlook?
The company expects its current cash, cash equivalents and marketable securities, as well as its retained portion of future royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs into fiscal 2029. Source: Nexqual (nexqual.com/earnings/2026-11-16/ENTA).
More on ENTA
ENTA stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 16, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 18, 2026 at 20:31 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 18, 2026 at 20:31 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt